Alkermes plc (ALKS)

From the record

Alkermes plc's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Alkermes plc's 10 filed years say what it did: revenue went from $746 million in fiscal 2016 to $1.5 billion in fiscal 2025, up 7.9% a year; it rose in 5 of 9 years; the deepest fall was 11% from fiscal 2019 to fiscal 2020; net income was positive in 3 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Alkermes plc's diluted share count grew about 1.0% a year, and dividends and buybacks returned about 15% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 33 sales (31 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-03 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Alkermes plc earned about 13 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 51 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count shrank 0.3% over the year (the filed statements).

From the record

Alkermes plc's standing among 315 graded names in its industry family: revenue of $1.5 billion in fiscal 2025 ranks in the top 10% by size; a net margin of 16.4% ranks in the top 13%; revenue growth of 9.9% a year over the last 3 filed years ranks in the top 48% (its annual reports).

From the record

Alkermes plc's leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 16 officers and directors filing in the last fifteen months have been on the record a median of 6.2 years (top 37%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (bottom 31%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Alkermes plc's room to grow, from the newest filed statements (fiscal 2025): cash of $389 million against no long-term debt tagged leaves 15.6% of its assets as net cash, bottom 33% of its family; cash from operations less capital spending is 32.5% of revenue (top 6%); a gross margin of 86.7% (top 25%); research spending of 22% of revenue (bottom 28%) (its annual report).

From the record

Alkermes plc's growth drivers, from the filed years to fiscal 2025: revenue grew 9.9% a year over the last three filed years against 7.9% over all 10, speeding up (top 25% of its family); the newest year grew -5.3% (bottom 32%); research spending grew 5.9% a year (top 45%); capital spending grew 1.9% a year (top 36%) (its annual reports). Alkermes plc reported 5 product lines in fiscal 2025: Vivitrol at $468 million (32%), Aristada and Aristada Initio at $370 million (25%), LYBALVI at $347 million (24%), and 2 more; 3 of 5 grew against the year before (its annual report).

From the record

Alkermes plc's newest year against its own record: revenue of $1.5 billion in fiscal 2025 came in 19.9% below the $1.8 billion its prior three years' pace pointed to (bottom 31% of its family); net income of $242 million against a prior three-year average of $188 million (top 42%); a net margin of 16.4% against 10.2% before (bottom 44%) (its annual reports).